Skip to main content
. 2023 May 16;41(24):3988–3997. doi: 10.1200/JCO.23.00562

FIG 2.

FIG 2.

Kaplan-Meier plot of (A) DOR, (B) PFS, and (C) OS in patients with cBTKi pre-treated MCL treated with pirtobrutinib. cBTKi, covalent Bruton tyrosine kinase inhibitor; DOR, duration of response; MCL, mantle-cell lymphoma; NR, not reached; OS, overall survival; PFS, progression-free survival.